Introduction and provision of medical abortion: A tale of two countries in which technology is necessary but not sufficient

Contraception

Volumn 83, Issue 4, 2011, Pages 322-329

  Winikoff, Beverly ^a   Hassoun, Danielle ^b   Bracken, Hillary ^a  

^a GYNUITY HEALTH PROJECTS   (United States)

^b DELAFONTAINE HOSPITAL   (France)

Author keywords

France, United States; Medical abortion; Mifepristone

Indexed keywords

METHOTREXATE; MIFEPRISTONE; MISOPROSTOL;

CONTRACEPTION; FRANCE; GESTATIONAL AGE; HEALTH CARE COST; HEALTH SERVICE; HUMAN; LAW; MEDICAL ABORTION; MEDICAL RESEARCH; MENSTRUATION; PATIENT SATISFACTION; PREGNANCY; PREGNANCY TERMINATION; REVIEW; UNITED STATES;

ABORTION, INDUCED; FEMALE; FRANCE; HUMANS; MIFEPRISTONE; MISOPROSTOL; PREGNANCY; UNITED STATES;

EID: 79952573531     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2010.08.009     Document Type: Review

References (32)

1. Ulmann A. The development of Mifépristone: a pharmaceutical drama in three acts. J Am Med Women's Assn 2000;55(3 Suppl).
2. Faucher P, Hassoun D. L'Interruption Volontaire de grossesse médicamenteuse. Estem 2005.
3. ANAES. Mars 2001.Recommandations pour la pratique clinique. Prise en charge de l'interruption volontaire de grossesse jusqu'à 14 semaines.
4. Vilain A. Les interruptions volontaires de grossesse en 2007. DRESS. Etudes et résultats No 713. December 2009.
5. Blayo C, Bourmeau A, Bureau A et al. 1992 Juin. Rapport sur la pratique de l'I.V.G. en France. Paris: Secrétariat d'État aux droits des femmes et à la consommation. ANCIC-INED.
6. Nisand I. L'IVG en France. Propositions pour diminuer les difficultés que rencontrent les femmes. Paris: Ministère de l'emploi et de la solidarité; 1999.
7. Jones R, Zolna M, Henshaw SK, Finer L. Abortion in the United States: incidence and access to services, 2005. Perspect Sex Reprod Health 2008;40:6-16.
8. Couzinet B, Le Strat N, Ulmann A, et al. Termination of early pregnancy by the progesterone antagonist RU 486 (Mifepristone). N Engl J Med 1986;315:1565-70. (Pubitemid 17055390)
9. Crowley WF. Progesterone antagonism: science and society. N Engl J Med 1986;315:1607-8.
10. Rosenfeld M. Conception of a controversy: the French doctor and his Pill to prevent pregnancy. The Washington Post 1986:C1.
11. Greenhouse S. Drug maker stops all distribution of abortion pill. The New York Times 1988:A1.
12. Statement of Ronald Chesemore, Associate Commissioner for Regulatory Affairs, before the Subcommittee on Regulation, Business Opportunities and Energy Committee on Small Business, US House of Representatives, November 19, 1990. Cited on 14 June 2005. Available at http://www.fda.gov/cder/archives/ mifepristone/ MIF000001.pdf.
13. AMA supports testing of French abortion pill. The New York Times 1990:A16.
14. Hilts PJ. U.S. defends border seizure of abortion pills. The New York Times 1992:A21.
15. Benten v. Kessler, slip op. at 12, No. CV-92-3161 (E.D.N.Y. July 14, 1992) cited in NARAL. Mifepristone and the impact of abortion politics on scientific research and women's health. Cited on 15 June 2005. Available at http://www.naral.org/Issues/science/ science-fs.cfm.
16. The White House, Office of the Press Secretary, January 22, 1993. Accessed on 15 June 2005. Available at: http://clinton6.nara. gov/1993/01/1993-01-22-we-must-free-science-and-medicine-fromthe- grasp-of-politics.html.
17. Leary WE. Broader uses seen for abortion pill. The New York Times 1993:A17.
18. Many women eager to test abortion pill. The New York Times 1994:43.
19. Lewin T. Group intensifies campaign to market abortion pill. The New York Times 1997:A21.
20. Creinin MD, Vittinghoff E. Methotrexate and misoprostol vs. misoprostol alone for early abortion, a randomized controlled trial. JAMA 1994;272:1190-5. (Pubitemid 24307637)
21. Hausknecht R. Methotrexate and misoprostol for induced abortion. N Engl J Med 1995;333:537-40.
22. Schaff EA, Eisenger SH, Franks P, Kim S. Methotrexate and misoprostol for early abortion. Fam Med 1996;28:198-208.
23. Jain JK, Mishell DR. A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy. N Engl J Med 1994;33:290-3. (Pubitemid 24236015)
24. Schaff EA, Stadalius RNC, Eisenger MD, Franks P. Vaginal misoprostol administered after mifepristone (RU486) for abortion. J Fam Pract 1997;44:353-60. (Pubitemid 27174895)
25. Creinin MD, Darney PD. Methotrexate and misoprostol for early abortion. Contraception 1993;48:339-47.
26. Alan Guttmacher Institute. Facts in Brief: Induced Abortion in the United States. New York: Alan Guttmacher Institute; 2005.
27. Hausknecht R. Mifepristone and misoprostol for early medical abortion: 18 months experience in the United States. Contraception 2003;67:463-5. (Pubitemid 36695111)
28. Personal communication, Danco Laboratories.
29. Fjerstad M. Planned parenthood medication abortion updates. Presented at Mifepristone Medical Abortion: Moving Forward in the Face of Adversity. New York, USA. June; 2005.
30. Finer LB, Wei J. Effect of mifepristone on abortion access in the United States. Obstet Gynecol 2009;114(3):62330.
31. Henshaw SK, Finer LB. The accessibility of abortion services in the United States, 2001. Perspect Sex Reprod Health 2003;35:16-24.
32. Van Bebber SL, Phillips KA, Weitz TA, Gould H, Stewart F. Patient costs for medication abortion: results from a study of five clinical practices. Womens Health Issues 2006;16:4-13. (Pubitemid 43246705)